Just two months ago, the incredible performance of new vaccines from Moderna and Pfizer had people cheering for an imminent end to the pandemic. But an onslaught of fast-spreading and potentially dangerous mutations of the virus changed that.
So now, even as pharma companies ramp up production in the early stages of a massive rollout, they are racing to retool their vaccine strategies. Robert Langreth reports that booster shots could give drugmakers a lucrative new revenue stream.
Researchers are scrambling to understand the biology of new coronavirus variants and the impact they might have on vaccine efficacy.
Around the world, concern is growing about the impact that new, faster-spreading variants of the SARS-CoV-2 virus will have on the pandemic.
In this episode of Coronapod, we discuss what these variants are, and the best way to respond to them, in the face of increasing evidence that some can evade the immunity produced by vaccination or previous infection.
News: ‘A bloody mess’: Confusion reigns over naming of new COVID variants
News: Fast-spreading COVID variant can elude immune responses
News: Could new COVID variants undermine vaccines? Labs scramble to find out
News: How to redesign COVID vaccines so they protect against variants
News: J&J’s one-shot COVID vaccine offers hope for faster protection
Doctors Without Waiting Rooms 